



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : L74999TG2016PLC109280

06.12.2024
Hyderabad

To
Corporate Relations Department,
BSE Limited

Sub: Outcome of Board Meeting held on 06.12.2024

We wish to inform that the Board of Directors in their meeting held today, i.e., 06.12.2024, inter-alia, considered and approved issue of upto 8,00,000 (Eight Lakh) equity shares Rs. 10/- (Rupees Ten Only) each upon conversion of Unsecured Loan from Promoters on a Preferential basis subject to necessary approvals, in accordance with the Companies Act, 2013 read with applicable rules and that it shall be at a price which shall be determined in accordance with provisions of chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended. (Details as Annexed).

The item regarding increase of authorized capital was not taken up as the same is not required for the present issue of equity shares.

Disclosures for above as required under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed herewith as **Annexure A**

The meeting commenced at 6:00 p.m. and concluded at 9:15 p.m.

This is for your information

for VANTA BIOSCIENCE LIMITED
(Scrip Code: 540729 | Scrip ID: VANTABIO)

VENKATA SATHYA MURALI DOKKA
CHIEF FINANCIAL OFFICER

**Vanta Bioscience Limited**

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : L74999TG2016PLC109280

Annexure A**Disclosures under Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

S No	Particulars	Details
1	Type of Securities proposed to be issued	Equity shares pursuant to conversion of unsecured loans from Promoters
2	Type of Issuance	Preferential Issue of upto 8,00,000 (Eight Lakh) equity shares Rs. 10/- (Rupees Ten Only) each upon conversion of Unsecured Loan from Promoters on a Preferential basis subject to necessary approvals, in accordance with the Companies Act, 2013 read with applicable rules and that it shall be at a price which shall be determined in accordance with provisions of chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended
3	Total Number of Securities proposed to be issued and the Total Amount for which the Securities will be issued (approximately)	Preferential Issue of upto 8,00,000 (Eight Lakh) equity shares Rs. 10/- (Rupees Ten Only) each upon conversion of Unsecured Loan from Promoters on a Preferential basis at a price determined in accordance with SEBI ICDR Regulations.
4	Name of the investors	Dopesh Raja Mulakala and S Chandra Sekhar Rao, Promoters
5	Post - allotment of Securities, outcome of the Subscription, Issue Price / Allotted Price (in case of Convertible Equity Share Warrants) ; Number of Investors	Relevant information if any, will be disclosed post allotment of securities/in due course of time Number of Investors – 2 (Two)
6	In case of Convertible Equity Warrants – Intimation on conversion of the Securities or	Not Applicable



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : L74999TG2016PLC109280

	lapse of the tenure of the Instrument	
7	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable